Concomitant JAK2 V617F-positive PV and BCR-ABL-positive CML with ruxolitinib and dasatinib

latest research on PV and CML

Citation: Blood Cancer Journal (2015) 5, e351; doi:10.1038/bcj.2015.77 Published online 2 October 2015 The combination of ruxolitinib and dasatinib was safe and effective in the treatment of concomitant PV and CML in this patient A Zhou1, E M Knoche1, E K Engle1, D A C Fisher1 and S T Oh1 1Division of Hematology, Washington University School of Medicine, St Louis, MO, USA […]

error: Content is protected !
Malcare WordPress Security